Effects of rosiglitazone on pigment epithelium-derived factor, matrix metalloproteinase-2, and transforming growth factor-β1 expressions in diabetic rats kidney
10.3760/cma.j.issn.1000-6699.2011.01.019
- VernacularTitle:罗格列酮对糖尿病大鼠肾脏色素上皮衍生因子、基质金属蛋白酶2及转化生长因子β1表达的影响
- Author:
Lixin TAN
;
Zhanjian WANG
- Publication Type:Journal Article
- Keywords:
Diabetic nephropathies;
Pigment epithelium-derived factor;
Matrix-metalloproteinase-2;
Transforming growth factor-β1;
Rosiglitazone
- From:
Chinese Journal of Endocrinology and Metabolism
2011;27(1):66-69
- CountryChina
- Language:Chinese
-
Abstract:
Forty-five male SD rats were divided into normal group, diabetic control group, and rosiglitazone treatment diabetic group.By the end of 12 weeks, the expressions of pigment epithelium-derived factor(PEDF), matrix metalloproteinase-2 (MMP-2), and transforming growth factor-β1 (TGF-β1) in the kidney were determined by immunohistochemistry and RT-PCR.The results showed that rosiglitazone decreased the increased kidney weight/body weight ratio, serum creatinine, blood ureanitrogen, urinary albumin excretion, triglyceride levels in diabetic rats (all P＜0.01).Rosiglitazone prevented the decreasing of protein expressions of PEDF and MMP-2 and the increasing of protein expression of TGF-β1 (all P＜0.01).PEDF mRNA showed a similar change,suggesting that renoprotection of rosiglitazone on diabetic rats may be mediated through regulating the expressions of PEDF, MMP-2, and TGF-β1.
